CANADY HELIOS™ COLD PLASMA

The Canady Helios Cold Plasma (CHCP) System is designed to deliver a non-thermal Cold Atmospheric Plasma (CAP) and Electromagnetic Field that targets cells, disrupts cellular homeostasis and eliminates the cell’s ability to reproduce and survive.

The CHCP System delivers a plasma beam that creates plasma species known as reactive oxygen and reactive nitrogen species (RNS and ROS) and an electromagnetic field referred to as the Plasma Treatment Electromagnetic Filed (PTEF).1

The Plasma Treatment Electromagnetic Field (PTEF)

Cold Atmospheric Plasma is used to selectively target cells in the PTEF and disrupt the cell’s ability to reproduce and survive

According to JCRI-ABTS Research, the PTEF created by the Plasma Spray causes Irreversible Electroporation (IRE) or openings in the cell’s membrane. 

The pore formation allows the RNS and ROS to  permeate the cells membrane reducing the cell’s viability leading to apoptosis (cell death).1, 2, 3, 4, 5, 7

The cold plasma is sprayed intraoperatively at the surgical margin after tumor removal. This process only takes 5-7 minutes.

Because it’s a non-thermal process (75-86° F), normal tissue is left unharmed, so it can be used safely on organs, around ducts and vessels, and near other vital structures.

The Application of Canady Helios™ Cold Plasma

STEP 1
Cancerous Tumor Located in Breast

STEP 2
Tumor Removed with Canady Hybrid Plasma Scalpel

STEP 3
Tumor Margins Sprayed with Canady Helios Cold Plasma (CHCP)

STEP 4
Step Four: Research Indicates that Microscopic Cancer Cells are Selectively Targeted with CHCP 5

STEP 5
CHCP Interrupts the Cell Cycle of the Cancer Cell, leading to Apoptosis (cell death) 4, 5, 6, 7

The Treatment Process

STEP 2
Tumor Removed with Canady Hybrid Plasma Scalpel

STEP 3
Tumor Margins Sprayed with Canady Helios Cold Plasma (CHCP)

STEP 5
CHCP Interrupts the Cell Cycle of the Cancer Cell, Reducing Viability, Leading to Apoptosis

STEP 1
Cancerous Tumor Located in Breast

STEP 4
Microscopic Cancer Cells are Selectively Targeted with CHCP

The Treatment Process

STEP 1
Cancerous Tumor Located in Breast

STEP 2
Tumor Removed with Canady Hybrid Plasma Scalpel

STEP 3
Tumor Margins Sprayed with Canady Helios Cold Plasma (CHCP)

STEP 4
Microscopic Cancer Cells are Selectively Targeted with CHCP

STEP 5
CHCP Interrupts the Cell Cycle of the Cancer Cell, Reducing Viability, Leading to Apoptosis

Plasma Classification

In addition to the advantages associated with surgical margin ablation, our preclinical investigations, supplemented by a multitude of published studies, indicate that CHCP-treated cancerous cells elicit the release of highly specific and immuno-stable antigens, potentially inducing a systemic response conducive to targeted immunotherapeutic applications or as complementary modalities alongside established standards of care.

The Canady Helios Cold Plasma System was proven safe in a successful FDA Phase 1 Clinical Trial. It is currently indicated for the ablation of soft tissue.